公开(公告)号：US20240099975A1

公开(公告)日：2024-03-28

申请号：US18517448

申请日：2023-11-22

Applicant: FUJIFILM Corporation

Inventor： Susumu SHIMOYAMA ,  Keiko SUZUKI ,  Mikinaga MORI ,  Takeshi MATSUMOTO ,  Shinji NAKAYAMA ,  Yasushi MOROHASHI ,  Toshifumi KIMURA

IPC: A61K9/127 ,  A61K9/00 ,  A61K31/4745 ,  A61K33/04 ,  A61K47/10 ,  A61K47/28 ,  A61K47/54 ,  A61P35/00

CPC classification number: A61K9/1271 ,  A61K9/0019 ,  A61K31/4745 ,  A61K33/04 ,  A61K47/10 ,  A61K47/28 ,  A61K47/544 ,  A61P35/00

Abstract: An object of the present invention is to provide an anti-tumor agent that exhibits a remarkably excellent anti-tumor effect. According to the present invention, there is provided an anti-tumor agent for curing cancer, the anti-tumor agent having a liposome which has an inner water phase and having an aqueous solution which is an outer water phase and disperses the liposome, in which the liposome encompasses topotecan or a salt thereof, a lipid constituting the liposome contains a lipid modified with polyethylene glycol, dihydrosphingomyelin, and cholesterol, the inner water phase contains an ammonium salt, and the topotecan or the salt thereof encompassed in the liposome is administered at a dose rate of 0.1 mg/m2 body surface area to 10 mg/m2 body surface area, in terms of topotecan per administration.

公开(公告)号：US20240099974A1

公开(公告)日：2024-03-28

申请号：US18516010

申请日：2023-11-21

Applicant: FUJIFILM Corporation

Inventor： Susumu SHIMOYAMA ,  Mikinaga Mori

IPC: A61K9/127 ,  A61K9/00 ,  A61K31/4745 ,  A61K33/04 ,  A61P35/00

CPC classification number: A61K9/1271 ,  A61K9/0019 ,  A61K31/4745 ,  A61K33/04 ,  A61P35/00

Abstract: An object of the present invention is to provide a treatment agent for Merkel cell cancer. According to the present invention, there is provided a treatment agent for Merkel cell cancer, having a liposome which has an inner water phase and having an aqueous solution which is an outer water phase and disperses the liposome, in which the liposome encompasses topotecan or a salt thereof, a lipid constituting the liposome contains a lipid modified with polyethylene glycol, dihydrosphingomyelin, and cholesterol, and the inner water phase contains an ammonium salt.

公开(公告)号：US20210213051A1

公开(公告)日：2021-07-15

申请号：US17219064

申请日：2021-03-31

Applicant: FUJIFILM Corporation

Inventor： Ken OKADA ,  Susumu SHIMOYAMA ,  Mikinaga MORI

IPC: A61K33/243 ,  A61K9/127 ,  A61K31/4745 ,  A61K31/704 ,  A61K31/404 ,  A61K31/282 ,  A61P35/00

Abstract: An object of the present invention is to provide a pharmaceutical formulation obtained by combining a liposome composition, in which liposomes encapsulate a drug, with a platinum preparation. According to the present invention, there is provided a pharmaceutical formulation including (A) a liposome composition in combination with (B) a platinum preparation, in which the liposome composition includes, as constitutional components of a liposome membrane, a hydrophilic polymer-modified diacylphosphatidylethanolamine; a dihydrosphingomyelin; and cholesterols, the liposome composition includes a drug and has an inner water phase containing ammonium sulfate, a molar ratio of sulfate ions in the inner water phase to the drug in an entire water phase is 0.36 or more, and the liposome composition and the platinum preparation are administered simultaneously or sequentially.